Literature DB >> 26855949

Smart CARS: optimized development of a chimeric antigen receptor (CAR) T cell targeting epidermal growth factor receptor variant III (EGFRvIII) for glioblastoma.

Marco Ruella1, Bruce L Levine1.   

Abstract

Entities:  

Year:  2016        PMID： 26855949      PMCID： PMC4716948          DOI： 10.3978/j.issn.2305-5839.2015.10.11

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  32 in total

1.  Chimeric antigen receptor T cells for sustained remissions in leukemia.

Authors:  Shannon L Maude; Noelle Frey; Pamela A Shaw; Richard Aplenc; David M Barrett; Nancy J Bunin; Anne Chew; Vanessa E Gonzalez; Zhaohui Zheng; Simon F Lacey; Yolanda D Mahnke; Jan J Melenhorst; Susan R Rheingold; Angela Shen; David T Teachey; Bruce L Levine; Carl H June; David L Porter; Stephan A Grupp
Journal:  N Engl J Med       Date:  2014-10-16       Impact factor: 91.245

2.  Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody.

Authors:  Edward B Reilly; Andrew C Phillips; Fritz G Buchanan; Gillian Kingsbury; Yumin Zhang; Jonathan A Meulbroek; Todd B Cole; Peter J DeVries; Hugh D Falls; Christine Beam; Jinming Gu; Enrico L Digiammarino; Joann P Palma; Cherrie K Donawho; Neal C Goodwin; Andrew M Scott
Journal:  Mol Cancer Ther       Date:  2015-03-02       Impact factor: 6.261

Review 3.  Adoptive immunotherapy for cancer.

Authors:  Marco Ruella; Michael Kalos
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

4.  Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.

Authors:  Marco L Davila; Isabelle Riviere; Xiuyan Wang; Shirley Bartido; Jae Park; Kevin Curran; Stephen S Chung; Jolanta Stefanski; Oriana Borquez-Ojeda; Malgorzata Olszewska; Jinrong Qu; Teresa Wasielewska; Qing He; Mitsu Fink; Himaly Shinglot; Maher Youssif; Mark Satter; Yongzeng Wang; James Hosey; Hilda Quintanilla; Elizabeth Halton; Yvette Bernal; Diana C G Bouhassira; Maria E Arcila; Mithat Gonen; Gail J Roboz; Peter Maslak; Dan Douer; Mark G Frattini; Sergio Giralt; Michel Sadelain; Renier Brentjens
Journal:  Sci Transl Med       Date:  2014-02-19       Impact factor: 17.956

5.  Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.

Authors:  Richard A Morgan; Nachimuthu Chinnasamy; Daniel Abate-Daga; Alena Gros; Paul F Robbins; Zhili Zheng; Mark E Dudley; Steven A Feldman; James C Yang; Richard M Sherry; Giao Q Phan; Marybeth S Hughes; Udai S Kammula; Akemi D Miller; Crystal J Hessman; Ashley A Stewart; Nicholas P Restifo; Martha M Quezado; Meghna Alimchandani; Avi Z Rosenberg; Avindra Nath; Tongguang Wang; Bibiana Bielekova; Simone C Wuest; Nirmala Akula; Francis J McMahon; Susanne Wilde; Barbara Mosetter; Dolores J Schendel; Carolyn M Laurencot; Steven A Rosenberg
Journal:  J Immunother       Date:  2013-02       Impact factor: 4.456

6.  Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity.

Authors:  Hillary G Caruso; Lenka V Hurton; Amer Najjar; David Rushworth; Sonny Ang; Simon Olivares; Tiejuan Mi; Kirsten Switzer; Harjeet Singh; Helen Huls; Dean A Lee; Amy B Heimberger; Richard E Champlin; Laurence J N Cooper
Journal:  Cancer Res       Date:  2015-09-01       Impact factor: 12.701

7.  Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains.

Authors:  Carmine Carpenito; Michael C Milone; Raffit Hassan; Jacqueline C Simonet; Mehdi Lakhal; Megan M Suhoski; Angel Varela-Rohena; Kathleen M Haines; Daniel F Heitjan; Steven M Albelda; Richard G Carroll; James L Riley; Ira Pastan; Carl H June
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-11       Impact factor: 11.205

Review 8.  CAR T cells for solid tumors: armed and ready to go?

Authors:  Sunitha Kakarla; Stephen Gottschalk
Journal:  Cancer J       Date:  2014 Mar-Apr       Impact factor: 3.360

9.  EGFRvIII gene rearrangement is an early event in glioblastoma tumorigenesis and expression defines a hierarchy modulated by epigenetic mechanisms.

Authors:  C A Del Vecchio; C P Giacomini; H Vogel; K C Jensen; T Florio; A Merlo; J R Pollack; A J Wong
Journal:  Oncogene       Date:  2012-07-16       Impact factor: 9.867

Review 10.  Treatment related severe and fatal adverse events with cetuximab in colorectal cancer patients: a meta-analysis.

Authors:  Di Zhang; Junjie Ye; Tangpeng Xu; Bin Xiong
Journal:  J Chemother       Date:  2013-06       Impact factor: 1.714
View more
  5 in total

Review 1.  CAR T cell therapy as a promising approach in cancer immunotherapy: challenges and opportunities.

Authors:  Maryam Akhoundi; Mahsa Mohammadi; Seyedeh Saeideh Sahraei; Mohsen Sheykhhasan; Nashmin Fayazi
Journal:  Cell Oncol (Dordr)       Date:  2021-03-24       Impact factor: 6.730

Review 2.  Chimaeric antigen receptor T-cell therapy for tumour immunotherapy.

Authors:  Huan-Huan Sha; Dan-Dan Wang; Da-Li Yan; Yong Hu; Su-Jin Yang; Si-Wen Liu; Ji-Feng Feng
Journal:  Biosci Rep       Date:  2017-01-27       Impact factor: 3.840

Review 3.  EGFR as a Target for Glioblastoma Treatment: An Unfulfilled Promise.

Authors:  Manfred Westphal; Cecile L Maire; Katrin Lamszus
Journal:  CNS Drugs       Date:  2017-09       Impact factor: 5.749

4.  Highly Specific and Effective Targeting of EGFRvIII-Positive Tumors with TandAb Antibodies.

Authors:  Kristina Ellwanger; Uwe Reusch; Ivica Fucek; Stefan Knackmuss; Michael Weichel; Thorsten Gantke; Vera Molkenthin; Eugene A Zhukovsky; Michael Tesar; Martin Treder
Journal:  Front Oncol       Date:  2017-05-19       Impact factor: 6.244

5.  Human CD3+ T-Cells with the Anti-ERBB2 Chimeric Antigen Receptor Exhibit Efficient Targeting and Induce Apoptosis in ERBB2 Overexpressing Breast Cancer Cells.

Authors:  Rusheni Munisvaradass; Suresh Kumar; Chandramohan Govindasamy; Khalid S Alnumair; Pooi Ling Mok
Journal:  Int J Mol Sci       Date:  2017-09-08       Impact factor: 5.923
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.